Fibrous Dysplasia of Bone with Precocious Puberty and Elevated Serum Testosterone in Males

In males with fibrous dysplasia of bone, the presence of precocious puberty alongside elevated serum testosterone and/or advanced bone age defines a specific clinical situation that calls for targeted endocrine management in addition to standard bone-directed care.

Clinical scenario

Treatment for precocious puberty is indicated when there is an associated elevated serum testosterone and/or bone age advancement. This combination also requires monitoring for central precocious puberty, which may shift the therapeutic approach.

Treatment approach

When central precocious puberty is identified in this setting, addition of a gonadotropin-releasing hormone analogue (GnRHa) is part of the structured approach. The complete regimen — including sequencing, co-interventions, and monitoring criteria — is detailed in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1186/s13023-019-1102-9

Treatment for precocious puberty is indicated in case of an associated elevated serum testosterone and/or bone age advancement.
Combination of testosterone receptor blocker and aromatase inhibitor are needed as well as monitoring for central precious puberty, in which case GnRHa may need to be added.

View source ↗